Table 3.
Effects of chloroquine(CQ) intervention on resveratrol treatment in MCD medium induced-NASH
| Control | MCD | MCD + R | MCD + R + CQ | MCD + CQ | |
|---|---|---|---|---|---|
| ALT(U/L) | 29.5 ± 4.6 | 83.6 ± 6.4* | 38.5 ± 5.9 | 57.6 ± 7.3△△ | 94.7 ± 11.8▲▲ |
| AST(U/L) | 32.9 ± 3.1 | 100.2 ± 10.5* | 51.0 ± 6.4 | 73.0 ± 8.1△△ | 112.5 ± 12.4▲ |
| TG (μg/mg Pro) | 86.7 ± 9.2 | 294.5 ± 28.9** | 139.8 ± 16.2 | 229.6 ± 21.5△△ | 381.0 ± 36.1▲▲ |
| TBARs (μmol/g Pro) | 12.1 ± 1.2 | 43.5 ± 4.7** | 23.9 ± 2.4 | 27.1 ± 2.6△ | 53.6 ± 5.5▲▲ |
| ROS | 1.0 ± 0.2 | 6.6 ± 1.3** | 2.4 ± 0.3 | 3.6 ± 0.7△△ | 9.8 ± 1.14▲▲ |
| IL-1β (pg/ml) | 25.1 ± 3.3 | 89.7 ± 12.3** | 40.3 ± 4.3 | 68.3 ± 8.1△△ | 147.3 ± 13.3▲▲ |
| IL-6 (pg/ml) | 78.6 ± 5.8 | 285.5 ± 32.3** | 185.1 ± 16.4 | 207.8 ± 21.6△△ | 358.6 ± 33.1▲▲ |
| TNF-α (pg/ml) | 121.3 ± 12.9 | 792.4 ± 82.7** | 285.9 ± 25.7 | 541.3 ± 58.4△△ | 1043.9 ± 112.7▲▲ |
| IL-1β mRNA | 1.0 ± 0.1 | 3.2 ± 0.4** | 1.3 ± 0.1 | 1.9 ± 0.2 | 7.4 ± 0.9▲▲ |
| IL-6 mRNA | 1.0 ± 0.2 | 5.7 ± 0.6** | 2.2 ± 0.4 | 3.5 ± 0.4△ | 8.9 ± 1.1▲▲ |
| TNF-α mRNA | 1.0 ± 0.1 | 8.7 ± 0.9** | 1.7 ± 0.3 | 3.6 ± 0.5△ | 14.3 ± 1.8▲▲ |
Values are means ± SD, n = 3; MCD: methionine/choline-deficient medium
R resveratrol (100 μmol/L), CQ chloroquine
* P < 0.05, ** P < 0.01 compared to Control
△ P < 0.05, △△ P < 0.01 compared to MCD + R
▲ P < 0.05, ▲▲ P < 0.01 compared to MCD + R + CQ